Noninvasive evaluation of the malignant potential of intracranial meningiomas performed using proton magnetic resonance spectroscopy

Abstract

Proton MR spectroscopy is a useful diagnostic method for determining the proliferative or malignant potential of meningiomas according to the Cho/Cr ratio. A lactate and/or methylene signal suggests a high-grade tumor.

Diffusion-Weighted MR Imaging: Diagnosing Atypical or Malignant Meningiomas and Detecting Tumor Dedifferentiation

“…31 Several methods, including positron-emission tomography, perfusion MR imaging, and MR spectroscopy, have been proposed to study tumor grading and malignant progression in glial neoplasms. [32][33][34][35][36][37] Spectroscopic methods in particular may be useful in eliciting the metabolic correlates of genetic progression of gliomas or the malignant potential of meningiomas 38,39 during follow-up neuro-oncologic imaging. The role of decreasing ADC as a biomarker of worsening histologic grade has been less widely studied in intracranial neoplasms [40][41][42] (M.S.…”

Monovoxel ¹H Magnetic Resonance Spectroscopy in the Progression of Gliomas

“…Nuclear density was found to correlate with Cho values [19, 35, 36]. Correlations with MIB-1 and Ki-67 were found in proliferative meningioma [37], and in cerebral tumours [4, 38, 39]. In vitro, Sabatier et al [40] showed a significant rise in Cho with tumour grade, and in vivo, there was a correlation between Cho and tumour grade [5, 11, 17, 20, 22,41,42,43,44].…”

“…They increase in the presence of necrosis, and are generally characteristic of high-grade tumours [12, 13, 19, 20, 48,65,66,67,68]. Some authors have tried to separate primary neoplasm and metastasis [17, 66], metastasis of different origins [69] and tumours and meningiomas [18, 37] using lipids. There is a great signal variability for the same tumour type [11, 16, 17, 28, 44, 62, 70, 71].…”

Spectroscopy: 1 H Metabolite Concentrations

“…Alanine tends to be particularly elevated in tumours of meningeal origin (Florian et al, 1995) and is present at MRS-visible concentrations in a significant proportion of, but not all, meningiomas [12 out of 30, in a series reported by Shino et al (1999)]. An example is shown in Figure 9.9(d).…”